Sunshine Biopharma Inc: closes offering raising about $6,000,000

What happened

• Sunshine Biopharma Inc reported that on Oct 8, 2026 it entered into a placement agent agreement with Aegis Capital Corp. The company reported that the related best efforts public offering closed on Oct 9, 2026 and produced gross proceeds of approximately $6,000,000.

Key details

• The offering comprised 10,509,082 common units at $0.55 per unit and 400,000 pre-funded units at $0.54999 per unit.
• Each common unit consisted of 1 share of common stock and 2 Series D warrants; each pre-funded unit consisted of 1 pre-funded warrant and 2 Series D warrants.
• The pre-funded warrants were immediately exercisable at $0.00001 and were exercised in full prior to closing. The Series D warrants are immediately exercisable at $0.66 per share and expire in 5 years; a share-combination adjustment may reduce the exercise price to no less than $0.275 and may increase the number of shares, subject to limitations and any required Nasdaq shareholder approval.
• The placement agent received a fee of 7% of the public offering price and a non-accountable expense allowance of 1% of the public offering price; the offering was made under an effective registration statement on Form S-1 declared effective Oct 7, 2026.

Why it may matter

• The report includes Item 1.01 (entry into a material definitive agreement) describing the placement agent agreement and the terms of the offering, and Item 8.01 reporting press releases dated Oct 8, 2026 and Oct 9, 2026 announcing pricing and closing. This filing does not show why the insider traded or why the company acted.